Search results
17 sie 2023 · Prevnar 13®, the 13-valent PCV, was able to cover 76% of strains responsible for children under the age of five, with an estimated 78% reduction in IPD vaccine-related serotypes after ...
1 lut 2024 · We assessed cases of IPD that were breakthrough infections or vaccine failures in individuals eligible for the 1 + 1 schedule (born between Jan 1, 2020, and Dec 31, 2022) who developed IPD in 2022–23 compared with three birth cohorts of the same age range who had been eligible for the 2 + 1 schedule and developed disease during 2017–18 ...
On the other hand, PCV is effective for infants, helps build immune memory, and reduces the occurrence of pneumococcal bacteria. Currently, most European vaccination programs prefer using PCV as their primary pneumococcal vaccine.
deaths occur in developing countries where few children have access to life-saving serotype-based vaccines. Understanding the serotype epidemiology of invasive pneumococcal disease (IPD) among children is necessary for vaccine development and introduction policies. The aim
8 sie 2022 · Existing literature on invasive pneumococcal disease (IPD) in children currently available strongly focuses on demonstrating vaccine effectiveness following pneumococcal conjugate vaccine (PCV) implementation, and particularly in young children (<5 years) that are at highest risk.
16 lis 2012 · Results: 13 culture-confirmed vaccine-type cases of invasive pneumococcal disease were detected in infants starting vaccination at less than seven months of age: none in the PHiD-CV10 3+1 group, one in the PHiD-CV10 2+1 group, and 12 in the control groups.
Pneumococcal conjugated vaccines have been recommended in children for over a decade in many countries worldwide. Here we review the development of pneumococcal vaccines with a focus on the two types currently available for children and their safety record.
